Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity (2020 - 2023)

Cullinan Therapeutics has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $494.7 million for Q3 2023.

  • Quarterly results put Liabilities and Shareholders Equity at $494.7 million for Q3 2023, down 19.85% from a year ago — trailing twelve months through Dec 2023 was $1.5 billion (down 32.91% YoY), and the annual figure for FY2022 was $561.1 million, up 28.35%.
  • Liabilities and Shareholders Equity for Q3 2023 was $494.7 million at Cullinan Therapeutics, down from $522.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CGEM hit a ceiling of $667.2 million in Q2 2022 and a floor of $214.7 million in Q4 2020.
  • Median Liabilities and Shareholders Equity over the past 4 years was $487.2 million (2021), compared with a mean of $488.7 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 103.62% in 2021 and later decreased 21.77% in 2023.
  • Cullinan Therapeutics' Liabilities and Shareholders Equity stood at $214.7 million in 2020, then surged by 103.62% to $437.2 million in 2021, then grew by 28.35% to $561.1 million in 2022, then decreased by 11.84% to $494.7 million in 2023.
  • The last three reported values for Liabilities and Shareholders Equity were $494.7 million (Q3 2023), $522.0 million (Q2 2023), and $515.0 million (Q1 2023) per Business Quant data.